Marinus Pharmaceuticals (MRNS) Competitors $0.23 -0.01 (-3.56%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MRNS vs. ITRM, IOBT, CELU, CASI, KZR, VTVT, OMGA, MAAQ, XCUR, and SNYRShould you be buying Marinus Pharmaceuticals stock or one of its competitors? The main competitors of Marinus Pharmaceuticals include Iterum Therapeutics (ITRM), IO Biotech (IOBT), Celularity (CELU), CASI Pharmaceuticals (CASI), Kezar Life Sciences (KZR), vTv Therapeutics (VTVT), Omega Therapeutics (OMGA), Mana Capital Acquisition (MAAQ), Exicure (XCUR), and Synergy CHC Corp. (Uplisting) (SNYR). These companies are all part of the "pharmaceutical products" industry. Marinus Pharmaceuticals vs. Iterum Therapeutics IO Biotech Celularity CASI Pharmaceuticals Kezar Life Sciences vTv Therapeutics Omega Therapeutics Mana Capital Acquisition Exicure Synergy CHC Corp. (Uplisting) Iterum Therapeutics (NASDAQ:ITRM) and Marinus Pharmaceuticals (NASDAQ:MRNS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings. Does the media refer more to ITRM or MRNS? In the previous week, Marinus Pharmaceuticals had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for Marinus Pharmaceuticals and 0 mentions for Iterum Therapeutics. Marinus Pharmaceuticals' average media sentiment score of 0.00 beat Iterum Therapeutics' score of -0.75 indicating that Marinus Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Iterum Therapeutics Negative Marinus Pharmaceuticals Neutral Do analysts recommend ITRM or MRNS? Iterum Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 182.49%. Marinus Pharmaceuticals has a consensus target price of $4.79, indicating a potential upside of 1,980.75%. Given Marinus Pharmaceuticals' higher probable upside, analysts plainly believe Marinus Pharmaceuticals is more favorable than Iterum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Marinus Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36 Which has preferable earnings & valuation, ITRM or MRNS? Iterum Therapeutics has higher earnings, but lower revenue than Marinus Pharmaceuticals. Iterum Therapeutics is trading at a lower price-to-earnings ratio than Marinus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIterum TherapeuticsN/AN/A-$38.37M-$2.00-0.89Marinus Pharmaceuticals$30.99M0.41-$141.40M-$2.47-0.09 Is ITRM or MRNS more profitable? Iterum Therapeutics has a net margin of 0.00% compared to Marinus Pharmaceuticals' net margin of -446.48%. Iterum Therapeutics' return on equity of 0.00% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Iterum TherapeuticsN/A N/A -160.85% Marinus Pharmaceuticals -446.48%-7,831.35%-120.74% Do insiders and institutionals hold more shares of ITRM or MRNS? 9.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 98.8% of Marinus Pharmaceuticals shares are held by institutional investors. 9.2% of Iterum Therapeutics shares are held by insiders. Comparatively, 5.5% of Marinus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community favor ITRM or MRNS? Marinus Pharmaceuticals received 296 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. Likewise, 67.54% of users gave Marinus Pharmaceuticals an outperform vote while only 62.95% of users gave Iterum Therapeutics an outperform vote. CompanyUnderperformOutperformIterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% Marinus PharmaceuticalsOutperform Votes43767.54% Underperform Votes21032.46% Which has more risk & volatility, ITRM or MRNS? Iterum Therapeutics has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, Marinus Pharmaceuticals has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. SummaryMarinus Pharmaceuticals beats Iterum Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Weiss RatingsNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …Find out details on these three critical Nvidia partners immediately. Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRNS vs. The Competition Export to ExcelMetricMarinus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.69M$6.57B$5.10B$9.08BDividend YieldN/A2.97%4.90%4.21%P/E Ratio-0.0910.5090.8717.14Price / Sales0.41195.381,112.67116.85Price / CashN/A57.1642.1437.88Price / Book0.745.104.784.78Net Income-$141.40M$151.51M$119.77M$225.60M7 Day Performance-12.48%-2.12%-1.87%-1.23%1 Month Performance-25.78%-3.11%11.46%3.07%1 Year Performance-97.63%11.52%30.49%16.48% Marinus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRNSMarinus Pharmaceuticals4.3106 of 5 stars$0.23-3.6%$4.79+1,980.7%-97.5%$12.69M$30.99M-0.09110Analyst ForecastNews CoverageITRMIterum Therapeutics2.0496 of 5 stars$1.88+4.4%$5.00+166.0%+6.0%$51.73MN/A-0.9410IOBTIO Biotech3.2828 of 5 stars$0.77-4.9%$9.33+1,112.0%-47.9%$50.74MN/A-0.5930News CoverageCELUCelularityN/A$2.29+3.2%N/A+36.9%$50.35M$48.20M0.00220CASICASI Pharmaceuticals3.089 of 5 stars$3.20+2.9%$6.00+87.5%-59.2%$49.48M$22.06M-1.39180Positive NewsKZRKezar Life Sciences3.6926 of 5 stars$6.72-0.4%$40.50+502.7%-25.0%$49.03M$7M-0.5160Analyst ForecastNews CoverageVTVTvTv Therapeutics2.0066 of 5 stars$15.30+1.8%$35.00+128.8%+70.4%$48.81M$2.02M-3.329OMGAOmega Therapeutics2.0256 of 5 stars$0.88-9.1%$9.20+944.6%-62.8%$48.76M$3.09M0.00120MAAQMana Capital AcquisitionN/A$5.99-23.2%N/A-53.4%$48.67MN/A0.001Gap UpHigh Trading VolumeXCURExicure0.8894 of 5 stars$18.35+6.0%N/A+2,901.6%$47.89M$28.83M-9.2750News CoverageGap UpSNYRSynergy CHC Corp. (Uplisting)N/A$5.50+4.4%N/AN/A$47.85MN/A0.0040Positive NewsGap Up Related Companies and Tools Related Companies Iterum Therapeutics Competitors IO Biotech Competitors Celularity Competitors CASI Pharmaceuticals Competitors Kezar Life Sciences Competitors vTv Therapeutics Competitors Omega Therapeutics Competitors Mana Capital Acquisition Competitors Exicure Competitors Synergy CHC Corp. (Uplisting) Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MRNS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marinus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRNS Stock Alerts